Page 201 - Alps News Today

For some travellers, flying is an exciting adventure, but turbulent flights can turn it into a bumpy experience.

Westfield Capital Management Co. LP acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 237,495 shares of the biopharmaceutical company’s stock, valued at approximately $10,939,000. Westfield Capital Management Co. […]

Around 65,000 flights are estimated to encounter moderate turbulence every year - and about 5,500 encounter severe turbulence. Turbli has ranked the most turbulent flight routes

Operator: Good afternoon. My name is Regina and I will be your conference operator today. At this time, I would like to welcome everyone to NVIDIAs First Quarter Earnings Call.

A Singapore Airlines flight from Heathrow to Singapore was hit by severe turbulence, causing the death of one British man, and injuring many others.

Brits travelling to Lauterbrunnen in Switzerland could soon be charged a Venice-style entry fee following rising numbers of tourists crowding the village

Truist Financial reiterated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $17.00 price target on the stock. A number of other analysts also recently weighed in on ALLO. Royal Bank of Canada reiterated an outperform rating […]

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) CEO Timothy P. Noyes sold 10,000 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $21.58, for a total value of $215,800.00. The sale was disclosed in a document filed with the SEC, which can be […]

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 151,180 shares changed hands during trading, an increase of 15% from the previous session’s volume of 131,156 shares.The stock last traded at $20.38 and had previously closed at $19.28. Analysts Set New Price Targets Several research analysts have […]

Wedbush reaffirmed their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research note released on Tuesday, Benzinga reports. They currently have a $41.00 price target on the stock. Wedbush also issued estimates for Aerovate Therapeutics’ Q2 2024 earnings at ($0.71) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings […]